Radionuclide thyroid studies: a survey of practice in the United States in 1981. Special report.

Parker, Timothy W.; Fa, Mettler; Christie, James H.; Williams, Arvis G.

doi:10.1148/radiology.150.2.6318261

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The key informants indicated a different frequency of use in 1974: 24% for 131 I-sodium iodide, 7% for 123 I-sodium iodide, and 69% for 99m Tc-pertechnetate. For the year 1981 agreement is better, Parker et al (1984) reported that 9% of thyroid scans were conducted using 131 I-sodium iodide (vs 19% reported in this study), 35% with 123 I-sodium iodide (vs 23% in this study), and 54% with 99m Tc-pertechnetate (vs 59% in this study).…”

Section: Discussionmentioning

confidence: 51%

See 1 more Smart Citation

Use of Radiopharmaceuticals in Diagnostic Nuclear Medicine in the United States

Drozdovitch¹,

Brill²,

Callahan³

et al. 2015

Health Physics

View full text Add to dashboard Cite

To reconstruct reliable nuclear medicine-related occupational radiation doses or doses received as patients from radiopharmaceuticals over the last five decades, we assessed which radiopharmaceuticals were used in different time periods, their relative frequency of use, and typical values of the administered activity. This paper presents data on the changing patterns of clinical use of radiopharmaceuticals and documents the range of activity administered to adult patients undergoing diagnostic nuclear medicine procedures in the U.S. between 1960 and 2010. Data are presented for 15 diagnostic imaging procedures that include thyroid scan and thyroid uptake, brain scan, brain blood flow, lung perfusion and ventilation, bone, liver, hepatobiliary, bone marrow, pancreas, and kidney scans, cardiac imaging procedures, tumor localization studies, localization of gastrointestinal bleeding, and non-imaging studies of blood volume and iron metabolism. Data on the relative use of radiopharmaceuticals were collected using key informant interviews and comprehensive literature reviews of typical administered activities of these diagnostic nuclear medicine studies. Responses of key informants on relative use of radiopharmaceuticals are in agreement with published literature. Results of this study will be used for retrospective reconstruction of occupational and personal medical radiation doses from diagnostic radiopharmaceuticals to members of the U.S. radiologic technologist’s cohort and in reconstructing radiation doses from occupational or patient radiation exposures to other U.S. workers or patient populations.

show abstract

Section: Discussionmentioning

confidence: 51%

“…We compared the relative use of radiopharmaceuticals in diagnostic nuclear medicine procedures reported by key informants with a literature-based description of relative use (USDHEW 1968, 1976; Parker et al 1984; Mettler et al 1986). The only radiopharmaceuticals that can be compared with literature data are shown in Figs.…”

Section: Discussionmentioning

confidence: 99%

Use of Radiopharmaceuticals in Diagnostic Nuclear Medicine in the United States

Drozdovitch¹,

Brill²,

Callahan³

et al. 2015

Health Physics

View full text Add to dashboard Cite

show abstract

“…This result is surprising, since a random distribution of patients between these two categories of institutions would be expected to generate 4-h results that were a factor of two lower. A detailed analysis of the data showed the 4-h uptake measurements to be skewed toward the upper end of the nor- (Parker et al 1984) (Wall et al 1985) (UNSCEAR 1982) (UNSCEAR 1982) (UNSCEAR 1982) ma1 range of 4-15%. Conversely, the 24-h values were generally placed in the middle of the normal range of 8-30%.…”

Section: Uptake Resultsmentioning

confidence: 99%

“…Considering the typical administered activity for thyroid scintigraphy / uptakes to be about 2.0 MBq (Parker et al 1984;Task Force 1978) and for a thyroid uptake to be about 0.2 MBq, and assuming the same demographic data as summarized here (see Fig. 2), it is straightforward to show that thyroid cancer risk (induction) would be approximately 0.9 in 1,000.…”

Section: Patient Detrimentmentioning

confidence: 96%

“…The contribution of thyroid examinations to the total number of NM examinations carried out in Manitoba is, however, one of the lower values listed in Table 3 (approximately two times lower than the value reported in Sweden ) . Table 4 compares the relative frequency of administration of the different radionuclides used in Manitoba with the data from the U.S. for 1981 (Parker et al 1984).…”

Section: Indications For Thyroid Examinationsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Thyroid Procedures and Corresponding Radiation Doses in Manitoba: 1981-1985

Huda

Gordon²,

Id³

1990

Health Physics

View full text Add to dashboard Cite

Data on nuclear medicine thyroid examinations performed in Manitoba (population 1 million) from 1981-1985 were collected, with more detailed demographic data obtained on 1,100 consecutive patients between June 1987 and January 1988. An average of 2,081 patients were examined per year, 81% female and 19% male, representing 8.4% of all nuclear medicine procedures. Typical administered activity and associated HE per patient were 238.0 MBq and 1.5 mSv for 99mTc, 7.4 MBq and 1.2 mSv for 123I, and 0.33 MBq and 3.9 mSv for 131I. Based on NCRP risk estimates with explicit corrections for age, sex, and radionuclide used, it is estimated that the rate of thyroid cancer induction is unlikely to exceed 0.56 y-1, of which about 10% would be fatal. This estimate is about a factor of 4 less than that generated using more generally applicable radiation protection risk estimates averaged over both sexes and all ages in the general population. The replacement of 131I with the present mix of radiotracers used for thyroid evaluation has resulted in a reduction of the estimated population detriment by a factor of 3.6.

show abstract